Relmada Therapeutics, Inc. RLMD Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $23.02M-48.6% | $26.88M-41.8% | $29.81M-40.3% | $36.92M-25.0% | $44.82M-14.2% | ||
| $37.33M+8.8% | $32.22M-14.6% | $28.04M-32.8% | $33.6M-20.2% | $34.3M-25.9% | ||
| $60.34M-23.7% | $59.1M-29.6% | $57.84M-36.9% | $70.52M-22.8% | $79.12M-19.7% | ||
| -$60.34M+23.7% | -$59.1M+29.6% | -$57.84M+36.9% | -$70.52M+22.8% | -$79.12M+19.7% | ||
| $1.47M-57.0% | $1.72M-56.2% | $1.67M-67.7% | $2.72M-40.5% | $3.41M-19.5% | ||
| -$58.88M+22.2% | -$57.39M+28.3% | -$56.17M+35.0% | -$67.81M+21.8% | -$75.71M+19.7% | ||
| -$1.11+55.8% | -$1.47+44.5% | -$1.80+37.1% | -$2.22+22.6% | -$2.51+19.6% | ||
| -$60.34M+23.7% | -$59.1M+29.6% | -$57.84M+36.9% | -$70.52M+22.8% | -$79.12M+19.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Relmada Therapeutics, Inc. profitable?
- Relmada Therapeutics, Inc. is not currently profitable: it reported a net loss of $58.9M over the trailing twelve months.
- What is Relmada Therapeutics, Inc.'s earnings per share?
- Relmada Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-1.11.
- Where does Relmada Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Relmada Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.